Wave Life Sciences (WVE) Total Current Liabilities (2014 - 2026)
Wave Life Sciences' (WVE) quarterly Total Current Liabilities came in at $50.8 million in Q2 2026, down 41.86% YoY from $87.4 million in Q2 2025, and up 1.97% on a QoQ basis from $49.8 million in Q1 2026.
Wave Life Sciences (WVE) Total Current Liabilities (2014 - 2026) Analysis & Trends
Wave Life Sciences (WVE) has 13 years of Total Current Liabilities data on file, last reported at $50.8 million in Q2 2026.
- Quarterly Total Current Liabilities fell 41.86% year-over-year to $50.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $50.8 million (down 41.86% YoY) and the FY2025 annual result came in at $95.1 million, down 14.32% from the prior year.
- Total Current Liabilities climbed to $50.8 million in Q2 2026, from $49.8 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $186.4 million in Q4 2023 to a low of $49.8 million in Q1 2026.
- A 5-year average of $105.3 million and a median of $91.2 million in 2025 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2023 — Total Current Liabilities jumped 160.68% — and 2025, when it slumped 49.69%.
- Tracing WVE's Total Current Liabilities over 5 years: stood at $71.5 million in 2022, then surged by 160.68% to $186.4 million in 2023, then plunged by 40.49% to $111.0 million in 2024, then slipped by 14.32% to $95.1 million in 2025, then slumped by 46.55% to $50.8 million in 2026.
- The last three Total Current Liabilities figures came in at $50.8 million (Q2 2026), $49.8 million (Q1 2026), and $95.1 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Wave Life Sciences | 1.05 Bn | 677.62 Mn | - | 50.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 50.82 Mn |
| Mar 31, 2026 | 49.83 Mn |
| Dec 31, 2025 | 95.07 Mn |
| Sep 30, 2025 | 85.90 Mn |
| Jun 30, 2025 | 87.41 Mn |
| Mar 31, 2025 | 87.37 Mn |
| Dec 31, 2024 | 110.95 Mn |
| Sep 30, 2024 | 170.73 Mn |
| Jun 30, 2024 | 173.13 Mn |
| Mar 31, 2024 | 165.87 Mn |
| Dec 31, 2023 | 186.44 Mn |
| Sep 30, 2023 | 99.98 Mn |
| Jun 30, 2023 | 140.23 Mn |
| Mar 31, 2023 | 132.57 Mn |
| Dec 31, 2022 | 71.52 Mn |
| Sep 30, 2022 | 64.26 Mn |
| Jun 30, 2022 | 64.08 Mn |
| Mar 31, 2022 | 58.49 Mn |
| Dec 31, 2021 | 64.20 Mn |
| Sep 30, 2021 | 31.64 Mn |